Principal Street Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Principal Street Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$988K	Buy	1,988 +1	+0.1%	+$443	0.14%	95
2026 Q1	$887K	Buy	1,987 +2	+0.1%	+$933	0.14%	85
2025 Q4	$900K	Sell	1,985 -360	-15%	-$155K	0.15%	83
2025 Q3	$918K	Sell	2,345 -1,526	-39%	-$638K	0.15%	85
2025 Q2	$1.72M	Buy	3,871 +1,535	+66%	+$707K	0.17%	83
2025 Q1	$1.13M	Buy	2,336 +78	+3%	+$36.3K	0.21%	69
2024 Q4	$909K	Sell	2,258 -752	-25%	-$349K	0.18%	74
2024 Q3	$1.41M	Buy	3,010 +629	+26%	+$302K	0.23%	71
2024 Q2	$1.12M	Sell	2,381 -29	-1%	-$12.6K	0.2%	69
2024 Q1	$1.01M	Buy	2,410 +177	+8%	+$74.8K	0.19%	71
2023 Q4	$909K	Sell	2,233 -102	-4%	-$37.7K	0.22%	73
2023 Q3	$812K	Sell	2,335 -117	-5%	-$40.9K	0.16%	97
2023 Q2	$863K	Sell	2,452 -28	-1%	-$9.43K	0.21%	77
2023 Q1	$781K	Sell	2,480 -974	-28%	-$292K	0.2%	77
2022 Q4	$997K	Sell	3,454 -291	-8%	-$88.7K	0.25%	66
2022 Q3	$1.08M	Buy	3,745 +153	+4%	+$44K	0.29%	64
2022 Q2	$1.01M	Sell	3,592 -479	-12%	-$128K	0.26%	66
2022 Q1	$1.06M	Sell	4,071 -351	-8%	-$83.3K	0.24%	71
2021 Q4	$971K	Buy	4,422 +1,603	+57%	+$312K	0.23%	75
2021 Q3	$512K	Sell	2,819 -1,463	-34%	-$286K	0.14%	117
2021 Q2	$864K	Sell	4,282 -4,783	-53%	-$1M	0.23%	87
2021 Q1	$1.95M	Buy	9,065 +4,631	+104%	+$1.02M	0.25%	77
2020 Q4	$1.05M	Buy	4,434 +229	+5%	+$52.5K	0.32%	71
2020 Q3	$1.14M	Sell	4,205 -150	-3%	-$41.4K	0.4%	67
2020 Q2	$1.26M	Buy	4,355 +134	+3%	+$36.3K	0.47%	57
2020 Q1	$1M	Sell	4,221 -1,005	-19%	-$231K	0.42%	49
2019 Q4	$1.14M	Sell	5,226 -1,691	-24%	-$342K	0.25%	68
2019 Q3	$1.16M	Buy	6,917 +2,928	+73%	+$518K	0.29%	61
2019 Q2	$732K	Buy	3,989 +434	+12%	+$75.9K	0.4%	74
2019 Q1	$654K	Buy	+3,555	New	+$657K	0.28%	52

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Principal Street Partners's VRTX Position: Q2 2026 in Review

Principal Street Partners increased its Vertex Pharmaceuticals (VRTX) stake by 0.05% in Q2 2026, buying an estimated $443 and bringing the position to 1,988 shares worth $988K. The position accounts for 0.14% of the portfolio, ranked #95.

Principal Street Partners first reported a position in VRTX in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.95M in Q1 2021. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Principal Street Partners held 1,988 shares of Vertex Pharmaceuticals worth $988K as of Q2 2026.
Principal Street Partners bought 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
Vertex Pharmaceuticals made up 0.14% of Principal Street Partners's portfolio in Q2 2026, its #95 holding.
Principal Street Partners first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
Principal Street Partners's Vertex Pharmaceuticals position peaked at $1.95M in Q1 2021.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Principal Street Partners's 13F filing for Q2 2026, filed 14 Aug 2026.